Canada Invests $80 Million in Precision Oncology to Expand Personalized Cancer Care
Health Canada announced an $80 million investment over four years to the Terry Fox Research Institute to support precision oncology research, aiming to enhance equitable access to personalized cancer care across the country.
On September 24, 2026, Honourable Marjorie Michel, Minister of Health, announced a significant financial commitment to advance cancer treatment in Canada. Speaking in Ottawa, Ontario, the Minister detailed an $80 million investment over four years directed to the Terry Fox Research Institute (TFRI). This funding is part of commitments made in Budget 2025 and aims to implement Phase 2 of the Marathon of Hope Cancer Centres Network.
The initiative focuses on precision oncology, a field that utilizes the genetic and biological makeup of cancer cells to determine personalized treatments. By tailoring therapies to individual patients, this approach seeks to reduce harmful side effects and improve the likelihood of treatment success. The Government of Canada’s contribution will be matched dollar-for-dollar by the TFRI and its network, unlocking a total of $160 million for precision oncology research.
The TFRI established the Marathon of Hope Cancer Centres Network, which has already created a data repository containing genome sequences from more than 16,000 patients. Under Phase 2, the network plans to add 11,000 new cases to this repository while strengthening systems for generating and analyzing genomic results. This expansion is designed to support workforce capacity in genomic data analysis and foster pan-Canadian collaboration.
Beyond data collection, the TFRI will onboard new cancer institutions to the Network, including those from Canadian territories, to ensure broader geographic representation. The institute also intends to work toward offering genetic testing for family members of patients with hereditary cancers. This investment reaffirms Canada's commitment alongside the G7 to accelerate the fight against cancer and enhance equitable access to advanced care across jurisdictions.